Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Aug 26, 2024; 16(8): 811-823
Published online Aug 26, 2024. doi: 10.4252/wjsc.v16.i8.811
Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor
Qi-Hong Chen, Ying Zhang, Xue Gu, Peng-Lei Yang, Jun Yuan, Li-Na Yu, Jian-Mei Chen
Qi-Hong Chen, Department of Critical Care Medicine, Jiangdu People’s Hospital of Yangzhou, Jiangdu People’s Hospital Affiliated to Yangzhou University, Yangzhou 225200, Jiangsu Province, China
Ying Zhang, Xue Gu, Peng-Lei Yang, Jun Yuan, Li-Na Yu, Department of Critical Care Medicine, Jiangdu People’s Hospital of Yangzhou, Yangzhou 225200, Jiangsu Province, China
Jian-Mei Chen, Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225000, Jiangsu Province, China
Author contributions: Chen QH designed the study and wrote the manuscript; Zhang Y participated in the cell culture and molecular biology experiments; Gu X performed the animal experiments and data acquisition; Yang PL contributed to the data acquisition and statistical analysis; Yuan J helped with the animal experiments and data acquisition; Yu LN performed the molecular biology experiments and statistical analyses; Chen JM contributed to research quality control and manuscript revision; All authors approved the final manuscript.
Supported by Research Project of Jiangsu Provincial Health Commission, No. Z2022008; and Research Project of Yangzhou Health Commission, No. 2023-2-27.
Institutional animal care and use committee statement: Animal care and interventions were performed in accordance with the National Institute of Health Guide for the Care and Use of Experimental Animals, and the animal protocol (YXYLL-2022-103) was approved by the Institutional Animal Care and Use Committees of the Yangzhou University School of Medicine.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available upon reasonable request from the corresponding author at 18051063567@163.com.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Mei Chen, PhD, Researcher, Institute of Translational Medicine, Medical College, Yangzhou University, No. 136 Jiangyang Middle Road, Hanjiang District, Yangzhou 225000, Jiangsu Province, China. 18051063567@163.com
Received: March 19, 2024
Revised: July 4, 2024
Accepted: August 15, 2024
Published online: August 26, 2024
Processing time: 159 Days and 23 Hours
Core Tip

Core Tip: Pulmonary fibrosis is strongly associated with poor outcomes in acute respiratory distress syndrome (ARDS) patients. Currently, there are no effective measures for treating pulmonary fibrosis. Microvesicles derived from mesenchymal stromal cells (MSC-MVs) have anti-pulmonary fibrosis effects; however, their specific effects and mechanisms in ARDS-related pulmonary fibrosis have not been fully established. This study revealed that MSC-MVs inhibited ARDS-related pulmonary fibrosis and fibrosis-related factors partly through hepatocyte growth factor, improved lung compliance and ventilation functions, and increased oxygenation indices. This study provides a new direction for the treatment of ARDS-related pulmonary fibrosis.